Pharmaceutical Technology
NOVEMBER 18, 2023
Basmisanil is a small molecule commercialized by F. Hoffmann-La Roche, with a leading Phase II program in Dup15q Syndrome.
Drug Patent Watch
NOVEMBER 18, 2023
This chart shows the pharmaceutical companies with the most patents in Russian Federation. Patents must be filed in each country (or, in some cases regional patent office) where patent protection… The post Which pharmaceutical companies have the most drug patents in Russian Federation? appeared first on DrugPatentWatch - Make Better Decisions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
NOVEMBER 18, 2023
TSC-200-A0201 is a gene-modified cell therapy commercialized by TScan Therapeutics, with a leading Phase I program in Metastatic Ovarian Cancer.
Pharmaceutical Technology
NOVEMBER 18, 2023
MRNA-4157 is a mrna vaccine commercialized by Merck, with a leading Phase II program in Metastatic Melanoma.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
NOVEMBER 18, 2023
Icovamenib is a small molecule commercialized by Biomea Fusion, with a leading Phase II program in Type 2 Diabetes.
Pharmaceutical Technology
NOVEMBER 18, 2023
Aflibercept Biosimilar. is a fusion protein commercialized by Celltrion, with a leading Phase III program in Diabetic Macular Edema.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
NOVEMBER 18, 2023
RPA-501 is a gene therapy commercialized by Rocket Pharmaceuticals, with a leading Phase II program in Glycogen Storage Disorders (GSD).
Pharmaceutical Technology
NOVEMBER 18, 2023
Aflibercept biosimilar is under clinical development by Amgen and currently in Phase III for Macular Edema.
Pharmaceutical Technology
NOVEMBER 18, 2023
MRNA-1083 is under clinical development by Moderna and currently in Phase III for Influenza A Virus, H3N2 Subtype Infections.
Pharmaceutical Technology
NOVEMBER 18, 2023
CMK-389 is under clinical development by Novartis and currently in Phase II for Pulmonary Sarcoidosis.
Expert insights. Personalized for you.
100 
Let's personalize your content